GlassScriptPhysician profile
Daniel H Brodtman
NPI 1881705390
$3,545.22
in general payments reported to CMS, 2019-2025
33 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $192 · 2021: $67.39 · 2022: $326 · 2023: $619 · 2024: $758 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Education: $50.25 · Consulting Fee: $26.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.92 |
| Education | $50.25 |
| Consulting Fee | $26.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $596.60 | 2020-2025 | Hyqvia, Glassia, Cuvitru |
| Astrazeneca Pharmaceuticals LP | $463.56 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $310.77 | 2020-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $304.28 | 2020-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $225.70 | 2023-2025 | |
| Csl Behring | $195.23 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Adma Biomanufacturing LLC | $151.35 | 2025 | |
| Genzyme Corporation | $141.27 | 2019-2025 | |
| Optinose US, INC. | $135.50 | 2020-2025 | |
| Ars Pharmaceuticals Operations, INC. | $104.59 | 2025 | Neffy |
| Genentech USA, INC. | $97.96 | 2019-2025 | Xolair |
| Pfizer INC. | $94.77 | 2022-2023 | |
| Kaleo, INC. | $75.21 | 2019-2024 | Auvi-Q |
| Pharming Healthcare, INC. | $70.94 | 2019-2023 | Ruconest |
| Organon LLC | $67.60 | 2025 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $50.14 | 2022-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $49.66 | 2025 | Nemluvio |
| Ionis Pharmaceuticals, INC. | $41.26 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $40.48 | 2022-2024 | Ayvakit |
| Kedrion Biopharma, INC. | $39.67 | 2025 | Kedrab, Koate, Gammaked |
| Shire North American Group INC | $38.36 | 2019 | |
| Insmed, INC. | $30.68 | 2023 | Arikayce |
| Lilly USA, LLC | $30.46 | 2024 | Ebglyss |
| Biocryst US Sales Co., LLC | $23.26 | 2023 | Orladeyo |
| Amgen INC. | $22.36 | 2025 | Tezspire |
| Cycle Pharmaceuticals INC | $21.42 | 2025 | Sajazir |
| Merck Sharp & Dohme LLC | $20.69 | 2023 | |
| Incyte Corporation | $19.37 | 2022 | |
| Arcutis Biotherapeutics, INC. | $17.88 | 2025 | Zoryve |
| Grifols USA, LLC | $17.41 | 2022 | |
| Circassia INC. | $17.36 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.11 | 2020 | |
| Aytu Biopharma, INC. | $14.32 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brodtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.